ZW25 (Zanidatamab) + Paclitaxel + Capecitabine + Vinorelbine + Tucatinib + Tucatinib

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HER2-expressing Cancers

Conditions

HER2-expressing Cancers

Trial Timeline

Sep 30, 2016 → Oct 31, 2024

NCT ID

NCT02892123

About ZW25 (Zanidatamab) + Paclitaxel + Capecitabine + Vinorelbine + Tucatinib + Tucatinib

ZW25 (Zanidatamab) + Paclitaxel + Capecitabine + Vinorelbine + Tucatinib + Tucatinib is a phase 1 stage product being developed by Jazz Pharmaceuticals for HER2-expressing Cancers. The current trial status is completed. This product is registered under clinical trial identifier NCT02892123. Target conditions include HER2-expressing Cancers.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02892123	Phase 1	Completed	Sep 30, 2016	Oct 31, 2024	HER2-expressing Cancers

Competing Products

6 competing products in HER2-expressing Cancers

See all competitors

Product	Company	Stage	Hype Score
SHR-4602	Jiangsu Hengrui Medicine	Phase 2	42
SHR-A1811 combined with Pyrotinib. + SHR-A1811 combined with other antitumor therapies	Jiangsu Hengrui Medicine	Phase 1/2	39
VIR-5818 + pembrolizumab	Merck	Phase 1/2	39
ZW25 (Zanidatamab) + Capecitabine + Cisplatin + Fluorouracil + Leucovorin + Oxaliplatin + Bevacizumab + Gemcitabine	Jazz Pharmaceuticals	Phase 2	32
Zanidatamab + Evorpacept	Jazz Pharmaceuticals	Phase 1/2	29
ZW49	Zymeworks	Phase 1	23